Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coherent, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Plans for a secondary offering of 3 mil. shares of common stock are outlined in a registration statement filed with the SEC. Santa Clara, California-based Coherent, which gained FDA approval in April for its Opal Photoactivator laser for use in photodynamic therapy with QLT PhotoTherapeutics' Visudyne (verteporfin for injection) to treat "wet" age-related macular degeneration (1"The Gray Sheet" April 17, In Brief), says it plans to use the proceeds "for acquisitions of and investments in businesses, technologies and products, continued development of new technologies and general corporate purposes." Underwriters UBS Warburg, CIBC World Markets, U.S. Bancorp Piper Jaffray and BlueStone Capital Partners will have an option for up to 450,000 overallotment shares
Advertisement

Related Content

QLT PhotoTherapeutics
QLT PhotoTherapeutics
Advertisement
UsernamePublicRestriction

Register

MT013557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel